Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms

Expert Opinion on Investigational Drugs

Volumn 25, Issue 12, 2016, Pages 1393-1403

  Bose, Prithviraj ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

epigenetic; essential thrombocythemia; Histone deacetylase inhibitors; JAK inhibitors; myelofibrosis; myeloproliferative neoplasms; polycythemia vera; rational combinations; ruxolitinib

Indexed keywords

GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; PANOBINOSTAT; PRACINOSTAT; RUXOLITINIB; VORINOSTAT; JANUS KINASE; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; BLEEDING; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; KIDNEY DYSFUNCTION; LEG ULCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; VOMITING; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SURVIVAL; THROMBOCYTHEMIA, ESSENTIAL;

ANIMALS; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HUMANS; JANUS KINASES; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PYRAZOLES; SURVIVAL; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84996598080     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1250882     Document Type: Review

References (120)

1. Dameshek W., Some speculations on the myeloproliferative syndromes. Blood. 1951 Apr;6(4):372–375.
2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405.• Key paper summarizing changes to the WHO classification of myeloid malignancies in the 2016 revision.
3. Rowley JD. Letter:a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973 Jun 1; 243(5405):290–293.•• Discovery of the Philadelphia chromosome, hallmark of CML.
4. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986 Jul 11; 233(4760):212–214.•• Demonstration that the protein product of the Philadelphia chromosome, BCR-ABL, causes CML.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19–25;365(9464):1054–1061.
6. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005 Apr 28;434(7037):1144–1148.
7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28;352(17):1779–1790.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387–397.•• Refs. [5–8], from different groups, represent the discovery of JAK2 V617F as a common activating mutation in MPN.
9. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007 Feb 1;356(5):459–468.• Discovery of JAK2 exon 12 mutations in PV.
10. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul;3(7):e270.• Discovery of MPL mutations in MF.
11. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders:a study of 1182 patients. Blood. 2006 Nov 15;108(10):3472–3476.
12. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379–2390.•• Discovery of CALR mutations in the majority of JAK2- and MPL-wild-type patients with ET or MF.
13. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19;369(25):2391–2405.•• Discovery of CALR mutations in the majority of JAK2- and MPL-wild-type patients with ET or MF.
14. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013 May 9;368(19):1781–1790.• Discovery of CSF3R mutations in the majority of patients with atypical CML and CNL.
15. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993 Oct;92(4):1736–1744.• Discovery of KIT mutations in SM.
16. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15;108(4):1377–1380.• Demonstration that JAK2 V617F is not necessarily the disease-initiating mutation in MPN.
17. Li J, Kent DG, Godfrey AL, et al. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood. 2014 May 15;123(20):3139–3151.• Demonstration that JAK2 V617F is a phenotypic driver mutation in MPN, but not the causal genetic event.
18. Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011 Aug 18;118(7):1723–1735.
19. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004 Nov 15;117(10):755–761.
20. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera:an international study. Leukemia. 2013 Sep;27(9):1874–1881.
21. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis:an international study. J Clin Oncol. 2012 Aug 20;30(24):2981–2987.
22. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms:critical concepts and management recommendations from european LeukemiaNet. J Clin Oncol. 2011 Feb 20;29(6):761–770.• ELN guidelines on management of MPN.
23. Anand S, Stedham F, Gudgin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood. 2011 Aug 11;118(6):1610–1621.• Demonstration that JAK-STAT activation in MPN does not correlate with mutational status of JAK2.
24. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 May 29;123(22):e123–33.• Demonstration that JAK-STAT signaling is universal across MPNs and key to MPN pathogenesis.
25. Verstovsek S, Mesa RA, Gotlib JR, et al. In:Long-term outcomes of ruxolitinib (RUX) therapy in patients (PTS) with myelofibroSIS (MF):5-year final efficaCY and safety analysis from comfort-I. EUROPEAN haematology association 21st Congress; 2016 Jun 9–12; Copenhagen p. S452.• Final results of the COMFORT-I trial, one of the pivotal studies leading to the regulatory approval of ruxolitinib.
26. Harrison CN, Vannucchi AM, Kiladjian J, et al. Long-term efficacy and safety in COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis:5-year final study results. Blood. 2015;126(23):59.• Final results of the COMFORT-II trial, one of the pivotal studies leading to the regulatory approval of ruxolitinib.
27. Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015 Sep;100(9):1139–1145.
28. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013 Jun 13;121(24):4832–4837.
29. Savona MR. Are we altering the natural history of primary myelofibrosis? Leuk Res. 2014 Sep;38(9):1004–1012.
30. Stein BL, Swords R, Hochhaus A, et al. Novel myelofibrosis treatment strategies:potential partners for combination therapies. Leukemia. 2014 Nov;28(11):2139–2147.
31. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10;27(32):5459–5468.
32. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005 Jun 10;23(17):3971–3993.
33. Mikkelsen TS, Ku M, Jaffe DB, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007 Aug 2;448(7153):553–560.
34. Ghirlando R, Felsenfeld G. CTCF:Making the right connections. Genes Dev. 2016 Apr 15;30(8):881–891.
35. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases:from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008 Mar;9(3):206–218.
36. Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action:emerging insights. Pharmacol Ther. 2014 Apr 24;143:323–336.
37. Yazbeck VY, Grant S. Romidepsin for the treatment of non-hodgkin’s lymphoma. Expert Opin Investig Drugs. 2015;24(7):965–979.
38. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3109–3115.• Pivotal trial of vorinostat in CTCL.
39. O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma:results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015 Aug 10;33(23):2492–2499.• Pivotal trial of belinostat in PTCL.
40. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631–636.• Pivotal trial of romidepsin in PTCL.
41. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011 Feb;25(2):226–235.
42. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes:results of the US leukemia intergroup trial E1905. J Clin Oncol. 2014 Apr 20;32(12):1242–1248.
43. Sekeres MA, Othus M, List AF, et al. Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML):North American intergroup study SWOG S1117. Blood. 2015;126(23):908.• Large cooperative group study showing lack of benefit of the addition of lenalidomide or vorinostat to azacitidine in higher risk MDS and CMML.
44. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22–33.•• Study that established 45% as the Hct goal in PV.
45. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426–435.•• Pivotal trial that led to approval of ruxolitinib for hydroxyurea-resistant/intolerant PV.
46. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis:a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Aug 21;29:2126–2133.
47. Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma. 2008 Dec;49(12):2321–2327.
48. Skov V, Larsen TS, Thomassen M, et al. Increased gene expression of histone deacetylases in patients with philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma. 2012 Jan;53(1):123–129.
49. Chen CQ, Yu K, Yan QX, et al. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases. Carcinogenesis. 2013 Jul;34(7):1442–1449.
50. Gao SM, Chen CQ, Wang LY, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol. 2013 Mar;41(3):261–270.e4.
51. Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008 Apr;22(4):740–747.
52. Akada H, Akada S, Gajra A, et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012 Apr 19;119(16):3779–3789.• Important preclinical paper demonstrating efficacy of vorinostat in an animal model of PV.
53. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009 Dec 3;114(24):5024–5033.• Demonstration of synergism between HDAC inhibitor and JAK2 inhibitor in MPN cells.
54. Fiskus W, Verstovsek S, Manshouri T, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011 Dec 1;17(23):7347–7358.• Demonstration of synergism between HSP90 inhibitor and JAK2 inhibitor in MPN cells.
55. Amaru Calzada A, Todoerti K, Donadoni L, et al. The HDAC inhibitor givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. Exp Hematol. 2012 Aug;40(8):634–645.e10.
56. Kaufmann KB, Grunder A, Hadlich T, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med. 2012 Jan 16;209(1):35–50.
57. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998 May 1;93(3):385–395.•• Seminal paper showing fundamental role of JAK2 in cytokine signaling.
58. Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009 Oct 8;461(7265):819–822.•• Seminal paper showing nuclear, noncanonical action of JAK2 in regulating gene expression.
59. Liu F, Zhao X, Perna F, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011 Feb 15;19(2):283–294.•• Seminal paper showing nuclear, noncanonical action of JAK2 in regulating gene expression.
60. Meyer SC, Levine RL. Molecular pathways:molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014 Apr 15;20(8):2051–2059.
61. Gautier EF, Picard M, Laurent C, et al. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood. 2012 Feb 2;119(5):1190–1199.
62. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000 Aug 29;97(18):10014–10019.
63. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2005 Jan 18;102(3):673–678.
64. Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA. 2010 Aug 17;107(33):14639–14644.
65. Brazelle W, Kreahling JM, Gemmer J, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010 Dec 14;5(12):e14335.
66. Bhaskara S, Chyla BJ, Amann JM, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell. 2008 Apr 11;30(1):61–72.
67. Ishii S, Kurasawa Y, Wong J, et al. Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci USA. 2008 Mar 18;105(11):4179–4184.
68. Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, et al. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res. 2007 Jul 1;67(13):6360–6367.
69. + MPN.
70. Adimoolam S, Sirisawad M, Chen J, et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA. 2007 Dec 4;104(49):19482–19487.
71. Kachhap SK, Rosmus N, Collis SJ, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010 Jun 18;5(6):e11208.
72. Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010 Sep;17(9):1144–1151.
73. Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol. 2003 Jun;23(12):4162–4173.
74. Shao W, Growney JD, Feng Y, et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models:defining molecular mechanisms of resistance. Int J Cancer. 2010 Nov 1;127(9):2199–2208.
75. Haan S, Wuller S, Kaczor J, et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 2009 Aug 27;28(34):3069–3080.
76. Amaru Calzada A, Pedrini O, Finazzi G, et al. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. Exp Hematol. 2013 Mar;41(3):253,60.e2.
77. Marubayashi S, Koppikar P, Taldone T, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest. 2010 Oct;120(10):3578–3593.• Established potential of therapeutically targeting the chaperone protein, HSP90, in MPN.
78. Kamishimoto J, Tago K, Kasahara T, et al. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. Cell Signal. 2011 May;23(5):849–856.
79. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90:a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005 Jul 22;280(29):26729–26734.• Showed that HDAC6 inhibitors acetylate and disrupt the function of HSP90, downregulating its client proteins.
80. Evrot E, Ebel N, Romanet V, et al. JAK1/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res. 2013 Nov 15;19(22):6230–6241.• Demonstration of synergism between HDAC inhibitor and JAK2 inhibitor in animal models of MPN.
81. Cardoso BA, Belo H, Barata JT, et al. The bone marrow-mediated protection of myeloproliferative neoplastic cells to vorinostat and ruxolitinib relies on the activation of JNK and PI3K signalling pathways. PLoS One. 2015 Dec 1;10(12):e0143897.
82. Shi J, Zhao Y, Ishii T, et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007 Jul 1;67(13):6417–6424.
83. Rosti V, Massa M, Vannucchi AM, et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007 May-Jun;38(3):280–286.
84. Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008 Aug;26(8):1920–1930.
85. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010 Aug;150(4):446–455.• The first clinical study to show activity of HDACi in MPN.
86. Finazzi G, Vannucchi AM, Martinelli V, et al. A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013 Jun;161(5):688–694.
87. Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013 Aug;162(4):498–508.
88. Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013 Apr;161(1):68–75.• Study suggesting that HDACi need to be given at low doses for prolonged periods for disease modification in MF.
89. DeAngelo DJ, Mesa RA, Fiskus W, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug;162(3):326–335.• Clinical trial of panobinostat in MF demonstrating downregulation of JAK-STAT signaling, lowering of cytokine levels and JAK2 V617F allele burden reduction.
90. Quintas-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep;36(9):1124–1127.
91. Harrison CN, Kiladjian JJ, Heidel FH, et al. Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF). Blood. 2015;126(23):4060.• The most mature clinical data available so far from a ruxolitinib–HDACi combination trial in MF.
92. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera:result of a european LeukemiaNet consensus conference. Blood. 2009 May 14;113(20):4829–4833.• ELN response criteria for PV and ET.
93. Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia:results of an initiative of the european myelofibrosis network (EUMNET). Blood. 2005 Oct 15;106(8):2849–2853.
94. Tefferi A, Barosi G, Mesa RA, et al. International working group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood. 2006 Sep 1;108(5):1497–1503.
95. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis:results of a european LeukemiaNet (ELN) consensus process. Br J Haematol. 2010 Mar;148(6):961–963.• Definitions of hydroxyurea resistance and intolerance in PV and MF.
96. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009 Mar 26;113(13):2895–2901.• The IPSS for PMF–the most widely used prognostic scoring system for newly diagnosed MF.
97. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera:80-week follow-up from the RESPONSE trial. Haematologica. 2016 Jul;101(7):821–829.
98. Vannucchi AM, Verstovsek S, Guglielmelli P, et al. In:Ruxolitinib (RUX) reduces JAK2V617F allele burden (AB) in patients (PTS) with polycythemia vera (PV) enrolled in the response study. European haematology association 21st congress; 2016 June 9–12; Copenhagen. p. S454.
99. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008 Oct 15;112(8):3065–3072.
100. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10;27(32):5418–5424.
101. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762–1769.
102. Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood. 2011 Mar 31;117(13):3658–3668.
103. Iancu-Rubin C, Gajzer D, Mosoyan G, et al. (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol. 2012 Jul;40(7):564–574.
104. Mascarenhas J, Roper N, Chaurasia P, et al. Epigenetic abnormalities in myeloproliferative neoplasms:a target for novel therapeutic strategies. Clin Epigenetics. 2011 Aug;2(2):197–212.
105. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 world health organization-defined essential thrombocythemia at diagnosis:a study by the international working group on myelofibrosis research and treatment. Blood. 2012 Aug 9;120(6):1197–1201.• Prognostic scoring system in ET.
106. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012 Dec 20;120(26):5128, 33; quiz 5252.• The most established scoring system for risk stratification for thrombosis in patients with ET.
107. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015 Nov 27;5:e369.
108. Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients:retrospective assessment in 1470 patients. Blood. 2014 Jun 12;123(24):3803–3810.
109. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms:when, which agent, and how? Blood. 2014 Dec 4;124(24):3529–3537.
110. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649–2655.
111. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322–1327.
112. Geyer HL, Mesa RA. Emerging drugs for the treatment of myelofibrosis. Expert Opin Emerg Drugs. 2015;20(4):663–678.
113. Andraos R, Qian Z, Bonenfant D, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012 Jun;2(6):512–523.
114. Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 6;489(7414):155–159.•• Preclinical demonstration of JAK2 inhibitor ‘persistence’ as a mechanism of acquired resistance.
115. Meyer SC, Keller MD, Chiu S, et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell. 2015 Jul 13;28(1):15–28.•• Demonstration of the ability of a new ‘type II’ JAK2 inhibitor to overcome type I JAK2 inhibitor persistence and resistance.
116. Verstovsek S, Mesa RA, Foltz LM, et al. PRM-151 in myelofibrosis:durable efficacy and safety at 72 weeks. Blood. 2015;126(23):56.
117. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015 Sep 3;373(10):908–919.
118. Durrant S, Nagler A, Vannucchi AM, et al. An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis:results from HARMONY study. Blood. 2015;126(23):827.
119. Gupta V, Harrison CN, Hasselbalch HC, et al. Phase 1b/2 study of the efficacy and safety of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Blood. 2015;126(23):825.
120. Daver N, Ruxolitinib VS. DNA methyltransferase-inhibitors:a foray into combination regimens in myelofibrosis. Leuk Lymphoma. 2015 Feb;56(2):279–280.